Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.

Publication

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.

Journal Paper/Review - Feb 3, 2023

Paluch-Shimon Shani, Neven Patrick, Huober Jens, Cicin Irfan, Goetz Matthew P, Shimizu Chikako, Huang Chiun-Sheng, Lueck Hans Joachim, Beith Jane, Tokunaga Eriko, Contreras Jessica Reyes, de Sant'Ana Rosane Oliveira, Wei Ran, Shahir Ashwin, Nabinger Sarah C, Forrester Tammy, Johnston Stephen R D, Harbeck Nadia

Citation

Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz M, Shimizu C, Huang C, Lueck H, Beith J, Tokunaga E, Contreras J, de Sant'Ana R, Wei R, Shahir A, Nabinger S, Forrester T, Johnston S, Harbeck N. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer. Ther Adv Med Oncol 2023; 15:17588359231151840.

Type

Journal Paper/Review (English)

Journal

Ther Adv Med Oncol 2023; 15

Publication Date

Feb 3, 2023

Issn Print

1758-8340

Pages

17588359231151840

Brief description/objective

Abemaciclib is the first and only cyclin-dependent kinases 4 and 6 inhibitor approved for adjuvant treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, and high-risk early breast cancer (EBC), with indications varying by geography. Premenopausal patients with HR+, HER2- tumors may have different tumor biology and treatment response compared to postmenopausal patients.